HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin
"HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Kyaw Zin Thein (ORCID: https://orcid.org/0000-0003-1518-1097)
- Hazem Aboaid (ORCID: https://orcid.org/0000-0002-3085-1549)
- Thura Win Htut (ORCID: https://orcid.org/0000-0002-5508-1472)
- Silvia Schauer
- Chalette Lambert-Swainston
- Ramaditya Srinivasmurthy
- Karl Aharonian
- Daniel T. Jones
- Rodd Rahmani
- Tal Schlesinger
- Abbas Hussain
- Riccesha Hattin
- Rory Twells
- Ryan Parto
Institutions
- University of Nevada, Las Vegas (US)
- Aberdeen Royal Infirmary (GB)
- Comprehensive Cancer Centers of Nevada (US)
- Touro University Nevada (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7313
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00